Safety and Tolerability Study of 131I-TM-601 to Treat Adult Patients With Recurrent Glioma.
Completed · Phase 1/Phase 2
Conditions studied: Glioma, Brain Neoplasm
In brief
This drug is being developed to treat a type of brain cancer, glioma. This study was designed to determine a safe and well tolerated dose. Patients must have had prior treatment for their glioma and be eligible for removal of their recurring tumor.
Key facts
- Study ID
- NCT00040573
- Run by
- TransMolecular
- People needed
- 18
- Starts
- 2002-06-01
- Expected to finish
- 2003-08-01
- Last updated by the study team
- 2009-03-31
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Alabama at Birmingham — Birmingham, Alabama, United States
- City of Hope — Duarte, California, United States
- Saint Louis University — St Louis, Missouri, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.